| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 602.14 | 8.2% | 3.9% |
| Total Income | 617.66 | 9.3% | 4.8% |
| Expenditure | 478.72 | 13.3% | 1.8% |
| PBT | 139.23 | 3.8% | 17.2% |
| Net Profit | 104.24 | 3.9% | 18.1% |
| OPM | 29.37% | 2.90pp | 2.18pp |
| NPM | 16.88% | 0.89pp | 1.90pp |
| EPS | 4.93 | 3.4% | 16.3% |
Sai Life Sciences: FY26 Revenue at ₹21,532.26 Mn
14 May 2026 · 14 May, 11:02 pm
Summary
SAI LIFE SCIENCES LIMITED delivered a strong financial performance for the fiscal year ended March 31, 2026, with revenue from operations growing by 31.13% year-on-year to ₹2,153.23 crore. The company's full-year profit after tax (PAT) saw a remarkable increase of 96.87%, reaching ₹341.48 crore. This was supported by a robust 51.74% growth in EBITDA, which stood at ₹649.09 crore. For the fourth quarter of FY26, revenue from operations increased by 4.82% to ₹594.34 crore, while PAT rose by 13.90% to ₹102.53 crore, indicating consistent growth across the periods.
Key Highlights
- 1
Revenue from operations for the full financial year FY26 significantly increased by 31.13% year-on-year, reaching ₹2,153.23 crore.
- 2
Profit after tax (PAT) for FY26 nearly doubled, demonstrating a substantial growth of 96.87% to ₹341.48 crore, compared to ₹173.46 crore in FY25.
- 3
The company's EBITDA for the fiscal year FY26 showed a robust growth of 51.74% year-on-year, amounting to ₹649.09 crore, with an EBITDA margin of 30.15%.
- 4
Basic Earnings Per Share (EPS) for FY26 improved significantly by 80.78% to ₹16.27, up from ₹9.00 in the previous fiscal year.
- 5
For the fourth quarter of FY26, revenue from operations was ₹594.34 crore, representing a 4.82% increase over the corresponding quarter in the previous year.
- 6
Q4 FY26 profit after tax grew by 13.90% year-on-year to ₹102.53 crore.
- 7
Profit before tax (PBT) for FY26 surged by 96.87% to ₹456.17 crore, reflecting strong profitability improvements.
Informational and educational content only. Not investment advice.